Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join us for the ACC Rockies Chapter Meeting from September 8-9, 2023 at the Hyatt Centric in Park City, Utah. For more information and to register, please visit: https://web.cvent.com/event/314c67f2-d26f-4ad9-bfd7-8011b1bd9dcb/summary
Latest in Cardiology from ACC.org
- Pulsed Field Ablation Noninferior to Cryoablation For Paroxysmal AFibPulsed field ablation (PFA) is noninferior to cryoablation for the incidence of a first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation (AFib), according to results from the SINGLE SHOT CHAMPION trial...
- Sharp Increase in Use of Tirzepatide, GLP1 RAs and SGLT2 inhibitors, As Conventional Alternatives DeclineAmong adults with type 2 diabetes (T2D), the use of tirzepatide along with GLP-1 RAs and SGLT2 inhibitors as glucose-lowering medication (GLM) has increased sharply, along with an increased use of tirzepatide and GLP-1 RAs as weight-lowering medication (WLM)...
- New HRS/ACC Scientific Statement Offers Guidance on Same-Day Discharge For Intracardiac Catheter AblationWith an increasing shift towards same-day discharge (SDD) as a means of improving access for an increasing number of patients undergoing intracardiac catheter ablation, a new Scientific Statement from the Heart Rhythm Society (HRS) and the ACC...
- PROSPECT II: High hsCRP Level Indicates High-Risk Vulnerable Plaque Post NSTEMIA high baseline level of high-sensitivity C-reactive protein (hsCRP) may indicate pan-coronary atherosclerosis and focal high-risk plaques in patients with a recent NSTEMI, according to a substudy of PROSPECT II published April 23...
- Beyond Glycemic Control: Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist to Reduce the Burden of Peripheral Artery DiseaseOver the past decade, lipid-lowering therapies have established the low-density lipoprotein-cholesterol dogma of the lower, the earlier, the longer, the better as the cornerstone of pharmacological prevention for atherosclerotic cardiovascular disease (ASCVD).
Become an ACC Member Today!
Already a Member?
Access your profile | Renew your membership | Personalize your ACC.org